Concert Pharmaceuticals Inc.’s recent filing unveils that its Director HUTT PETER BARTON unloaded Company’s shares for reported $21553.0 on Oct 14. In the deal valued at $6.09 per share,3,539 shares were sold. As a result of this transaction, HUTT PETER BARTON now holds 29,488 shares worth roughly $ 0.13 million.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Then, van Heek Christi bought 10,526 shares, generating $49,998 in total proceeds. Upon buying the shares at $4.75, the Director now owns 25,651 shares.
Before that, Auchincloss Thomas G bought 6,000 shares. Concert Pharmaceuticals Inc. shares valued at $28,500 were divested by the Director at a price of $4.75 per share. As a result of the transaction, Auchincloss Thomas G now holds 17,625 shares, worth roughly $78431.25.
Berenberg initiated its Concert Pharmaceuticals Inc. [CNCE] rating to a Buy in a research note published on Monday, December 16, 2020; the price target was $25. PT values the company’s stock at a premium of 82.2 to its Monday closing price. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late March with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering CNCE and reiterated its “Buy” recommendation on October 03, 2019. SunTrust started covering the stock on June 24, 2019. It rated CNCE as “a Buy”.
Price Performance Review of CNCE
On Monday, Concert Pharmaceuticals Inc. [NASDAQ:CNCE] saw its stock fall -20.11% to $4.45. On the same session, the stock had its day’s lowest price of $4.39, but rose to a high of $5.40. Over the last five days, the stock has lost -25.21%. Concert Pharmaceuticals Inc. shares have risen nearly 41.27% since the year began. Nevertheless, the stocks have risen 21.25% over the past one year. While a 52-week high of $7.37 was reached on 08/11/22, a 52-week low of $2.57 was recorded on 02/24/22. SMA at 50 days reached $6.21, while 200 days put it at $4.70. A total of 1.22 million shares were traded, compared to the trading of 0.61 million shares in the previous session.
Levels Of Support And Resistance For CNCE Stock
The 24-hour chart illustrates a support level at 4.09, which if violated will result in even more drops to 3.74. On the upside, there is a resistance level at 5.10. A further resistance level may holdings at 5.76. The Relative Strength Index (RSI) on the 14-day chart is 26.72, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.33, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.07%. Stochastics %K at 22.21% indicates the stock is a holding.
How much short interest is there in Concert Pharmaceuticals Inc.?
A steep rise in short interest was recorded in Concert Pharmaceuticals Inc. stocks on Jul 14, 2022, growing by 40000.0 shares to a total of 1.1 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 1.06 million shares. There was a rise of 3.64%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 2.57% of the overall stock float, the days-to-cover ratio (short ratio) rose to 2.64.
Concert Pharmaceuticals Inc. [CNCE] – Who Are The Largest Shareholders?
In filings from BVF Partners LP, it is revealed that the company now owns 3,629,000 shares, or roughly 7.57% of the outstanding CNCE shares. In other words, the investor’s shares have risen by 1,376,000 from its previous 13-F filing of 2253000.0. Additionally, RA Capital Management LP increased 9.02% of its stake after which the total value it holdings stand at $22,158,260. At present, Ingalls & Snyder LLC is holding 1,330,433 shares valued at $8.91 million. Millennium Management LLC owned 1,242,576 shares of the company at the time of its most recent 13F filing, worth $8.33 million.
According to FactSet, Concert Pharmaceuticals Inc.’s share price will average $17.40 in the next year, based on opinions of analysts polled by the firm. This is up nearly 205.21 percent from its previous closing price of $5.57. Analysts expect Concert Pharmaceuticals Inc. stock to reach the higher price of $25.00, while the lowest price estimate is $13.00. However, 5 analysts have rated CNCE stock as a Buy in their predictions for 2022.